

3<sup>rd</sup> Annual



# The Neurotech Industry Investing & Partnering Conference

*Advances in Drugs, Devices & Diagnostics for the Brain and Nervous System*

May 8-9, 2008 – Westin Copley Place, Boston MA

*Hear from over 50 speakers about next generation treatments for Alzheimer's, addiction, anxiety, depression, epilepsy, insomnia, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, stroke and other brain-related illnesses.*

The 3rd annual conference features keynotes on the state of the neurotech industry, cutting edge company presentations, and panel discussions on a comprehensive selection of neurotech topics of interest to biotech, medtech, and IT investors and executives.

- Find out who is investing in neurotech and why
- Discover emerging technologies and companies
- Learn about cutting edge research and funding opportunities
- Find out about new product licensing and partnering opportunities
- Get the latest market data and industry benchmarks

*Join leading investors, executives, entrepreneurs and others involved in the development of new treatments and diagnostics for the brain and nervous system in shaping the future of their organization and the industry.*

#### Advisory Board:

**Sam Barondes, MD**, *Director, Center Neurobiology & Psychiatry, UCSF*

**Zack Lynch**, *Executive Director, Neurotechnology Industry Organization*

**Nola Masterson**, *Managing Director, Science Futures*

**Dan O'Connell**, *Director, NeuroVentures Capital*

**Roger Quy, PhD**, *General Partner, Technology Partners*

**Nandini Tandon, PhD**, *Managing Director, MDS Capital*

#### Sponsors:



Register Before April 8<sup>th</sup> for Early Rates at [www.neuroinsights.com](http://www.neuroinsights.com)

**Thursday May 8, 2008**

 7:30 - 8:30 AM
 

---

**Breakfast & Registration**

 8:30 - 9:00 AM
 

---

**The Global Neurotech Industry**

NeuroInsights reveals updated proprietary market data, revenue projections, and industry trends for 2008.

**Zack Lynch**

*Executive Director, Neurotechnology Industry Organization*

 9:00 - 9:45 AM
 

---

**Investing in Neurotech**

A diverse panel of neurotech investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, and diagnostics?

**Alix Marduel\***

*Managing Director, Alta Partners*

**Art Pappas\***

*Managing Partner, Pappas Ventures*

**Roger Quy**

*General Partner, Technology Partners*

**Rajeev Shah**

*Senior Analyst, RA Capital*

**Moderator: Casey Crawford Lynch**

*Managing Director, NeuroInsights*

 9:45 - 10:15 AM
 

---

**Refreshment Break**

 10:15 - 11:15 AM
 

---

**Addiction, Impulsivity, Obesity**

Advancing science and acceptance of addiction as a brain disorder are creating opportunities for addressing unmet markets including nicotine, alcohol, and gambling. Treatments for addiction may also apply to the massive obesity market.

**Robert Alonso**

*President & CEO, Yaupon Pharmaceutica*

**Kenneth Chahine**

*President & CEO, Avigen*

**Mark Knudson**

*President & CEO, Enteromedics*

**Gary Tollefson**

*President & CEO, Orexigen*

**Session Chair: Selena Bartlett**

*Director, Preclinical Development Group, Ernest Gallo Clinic and Research Center*

 11:15 - 12:15 PM
 

---

**Drug Delivery and The Blood Brain Barrier**

The blood brain barrier keeps harmful substances and proteins from damaging the brain, but also prevents therapeutics from reaching their targets. Companies present novel approaches to giving abandoned leads new potential and utilizing the BBB to make treatments with fewer side effects.

**Peter Gaillard**

*President & CEO, toBBB*

**Lars Wahlberg**

*Executive VP & COO, NsGene*

**Erich Mohr**

*President & CEO, Med-Genesis*

**Wendye Robbins**

*President & CEO, Limerick Neuroscience*

**Session Chair: Frank Eeckman**

*NeuroInsights, Centient Biotech*

 12:15 - 1:30 PM Lunch Keynote
 

---

**David Ewing Duncan**

*Author and Commentator*

**The Experimental Man Project: The State of Neuroscience for the Average Man**

 1:30 - 2:30 PM
 

---

**Alzheimer's and Cognitive Disorders**

As the population ages, the market for Alzheimer's and cognitive disorders is exploding. In Alzheimer's symptomatic treatments are minimally effective. What is on the horizon for treating symptoms and slowing disease progression from drug and device companies?

**Kees Been**

*President & CEO, EnVivo Pharmaceuticals*

**Andres Lozano**

*CEO, Functional Neuroscience*

**Cris McReynolds**

*President & CEO, Satoris*

**Karoly Nikolich**

*Founder & CEO, Amnestix*

**Session Chair: Roger Quy**

*General Partner, Technology Partners*

 2:30 - 3:15 PM
 

---

**Paving the Way in New Markets: Case Studies and Panel**

As novel treatments become available for new indications, companies face challenges in paving regulatory and marketing pathways.

**Jonathan Kil**

*President & CEO, Sound Pharmaceuticals*

**Dan Moore**

*President & CEO, Cyberonics*

**Srinivas Rao**

*CSO, Cypress Bioscience*

**Moderator: Casey Lynch**

*Managing Director, NeuroInsights*

 3:15 - 3:45 PM
 

---

**Refreshment Break**

 3:45 - 4:45 PM
 

---

**Insomnia and Sleep Disorders**

A large late stage pipeline in sleep disorders leaves open the possibility of new competition for Ambien CR and Lunesta. How does recent FDA action on Indiplon impact development timelines of other late stage insomnia treatments? Will new mechanisms of action improve sleep maintenance? Can neurostimulation be used to treat sleep disorders?

**Robert Atkinson**

*President & CEO, Apnex Medical*

**David Hale**

*Executive Chairman, Somaxon*

**Sharon Mates**

*Chairman & CEO, Intra-Cellular Therapies*

**Tim Tasker**

*EVP Clinical Development, Evotec*

4:45 - 5:45 PM

### Traumatic Brain and Spinal Cord Injury

New hope is emerging for treatments of major traumatic injuries to the central nervous system. While venture funding may be scarce for such challenging areas, companies are leveraging government support and innovative financing to address these unmet markets.

**Gary Ascani**

*President & CEO, Banyan Biomarkers*

**Vincent Owens**

*President & CEO, Intelect Medical*

**Mark Pykett**

*President & COO, Alseres Pharma*

**Tim Surgenor**

*President & CEO, Cyberkinetics Neurotechnology Systems*

**Session Chair: Dan O'Connell**

*Managing Director, NeuroVentures Capital*

5:45 - 7:00 PM

### Cocktail Reception

## Friday May 9, 2008

7:30 - 8:30 AM

### Breakfast & Registration

8:30 - 9:15 AM

### Partnering and Licensing

Big pharma, biotech and medtech are increasingly looking for innovative product candidates to fill pipelines. What are current trends in strategic alliances and partnering?

**Kate Burt\***

*Director, Commercial Alliances & Transactions Worldwide Business Development, GlaxoSmithKline*

**Lothar Krinke**

*Vice President of Research & Business Development, Medtronic Neuromodulation*

**David Schulz**

*Senior Director, Worldwide Business Development, Pfizer*

\*confirming participation

**Virginia Smith-Swintoski**

*Manager of Scientific Licensing, CNS & Pain, Johnson & Johnson*

**Moderator: Christine de los Reyes**

*BioTech Partnering Solutions*

9:15 - 10:15 AM

### Next Gen Neuropsychiatry

Schizophrenia, anxiety, and depression represent a large portion of the neurotech market. What are the most promising next generation treatments? How will devices and diagnostics impact the treatment landscape?

**Philip Devlin**

*EVP & General Manager, Aspect Neuroscience*

**Luca Santarelli**

*Global Head of Clinical Research, CNS Hoffmann-La Roche*

**Jim Schoeneck**

*President & CEO, BrainCells, Inc.*

**Uzi Sofer**

*CEO, Brainsway*

**Session Chair: Manuel Lopez-Figueroa**

*Investment Professional, Bay City Capital*

10:15 - 10:45 AM

### Refreshment Break

10:45 - 11:30 AM

### Effective Clinical Trial Design

Intelligent clinical trial design is critical to the success of any neurotech venture. An insider panel will discuss tactics for improving the design of trials. Case studies reveal lessons learned in Alzheimer's, depression and more.

**Donald deBethizy**

*President & CEO, Targacept*

**Paul Gilbert**

*CEO, Medavante*

**Michael Kauffman**

*President & CEO, Epix Pharmaceuticals*

**Chris Chavez\***

*President & CEO, ANSI, St. Jude Medical*

**Moderator: Suzan Onel**

*Partner, K&L Gates, NIO Policy Counsel*

11:30 - 12:30 PM

### Pain: Acute, Chronic, and Neuropathic

New and innovative pain treatments are reaching the market ranging from abuse resistant opiate formulations to neurofeedback to neurostimulation. Companies are working towards treatments for neuropathic pain by targeting entirely new pathways.

**Neil Clark\***

*CEO, CeNeS*

**Christopher deCharms**

*President & CEO, Omneuron*

**Eliot Forster\***

*President and CEO, Solace Pharma.*

**Elliot Krames**

*President, International Neuromodulation Society, Co-Chair Nat'l Pain Foundation*

**Session Chair: T. (Teo) Forcht Dagi**

*Partner, HLM Venture Partners*

12:30 - 2:00 PM

### Partnering Lunch



2:00 - 3:00 PM

### Neurotech Public Policy

An overview and participant discussion of current and future congressional, FDA, and CMS initiatives currently active or being pursued to advance neurotech.

**Zack Lynch**

*Executive Director, NIO*

**Daniel Ritter**

*Partner, K&L Gates, NIO Public Policy Counsel*

**Suzan Onel**

*Partner, K&L Gates, NIO FDA Policy Counsel*

### Conference Concludes

3:00 - 3:30 PM

**Neurotech Industry Organization Annual Meeting**  
(members only)

## Reserve Your Place Now!

Register for **The Neurotech Industry Conference** in one of the following ways:

**Internet:** Log on to [www.neuroinsights.com](http://www.neuroinsights.com) and click on The Neurotech Industry Conference

**Mail:** You can mail your completed registration form (or a photocopy) along with your payment to:

NeuroInsights  
315 30<sup>th</sup> Street  
San Francisco, CA 94131

\*Make check payable to NeuroInsights

**Fax:** 415-358-5888

NeuroInsights will acknowledge your registration with a confirmation email.

**Email:** [conference@neuroinsights.com](mailto:conference@neuroinsights.com)

**Phone:** 415-229-3225

**Cancellation:** Cancellations received in writing by NeuroInsights before April 8<sup>th</sup> will receive a refund, minus a \$300 administration charge. Thereafter, refunds are not available. Substitutions may be made at any time by calling NeuroInsights at 415-229-3225.

### Conference Venue:

Westin Copley Place  
10 Huntington Ave  
Boston MA  
(617)262-9600

To receive the special hotel rate of \$269, mention "The Neurotech Industry Conference." Rate is available on a limited number of rooms.

### Media:

Please email [conference@neuroinsights.com](mailto:conference@neuroinsights.com) with your press pass request or for more information.

### Sponsors:

For more information contact  
Casey Lynch  
415-229-3225  
[Conference@neuroinsights.com](mailto:Conference@neuroinsights.com)  
[www.neuroinsights.com](http://www.neuroinsights.com)

## Please Register Me:

Before April 8, 2008

	Regular Attendee	\$1195
	NIO Member (list at <a href="http://www.neurotechindustry.org">www.neurotechindustry.org</a> )	\$995
	Start-up (seed or series A financing only)	\$995
	Academic or Nonprofit	\$795

After April 8, 2008

	Regular Attendee	\$1495
	NIO Member (list at <a href="http://www.neurotechindustry.org">www.neurotechindustry.org</a> )	\$1295
	Start-up (seed or series A financing only)	\$1295
	Academic or Nonprofit	\$1095

Name \_\_\_\_\_

Title \_\_\_\_\_

Company \_\_\_\_\_

Address \_\_\_\_\_

City/State/Zip \_\_\_\_\_

Telephone \_\_\_\_\_

Fax \_\_\_\_\_

Email for confirmation \_\_\_\_\_

How did you hear about the conference? \_\_\_\_\_

Please invoice me:

Payment enclosed:

Charge it on my: Visa  Mastercard  American Express

Name on Card \_\_\_\_\_

Billing Address \_\_\_\_\_

Card No. \_\_\_\_\_

Exp. Date \_\_\_\_\_

Signature \_\_\_\_\_


**NEUROINSIGHTS**

315 30<sup>th</sup> Street  
San Francisco, CA 94131